Who are human VWF/FVIII concentrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Traditional Cryoprecipitate, Kogenate (BAY 14-2222), Recombinant Factor VIII (rAHF), rFVIIIFc, Recombinant Human Coagulation FVIII, Intravenous infusions of Xyntha.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-vwf-fviii-concentrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

human VWF/FVIII concentrate — Competitive Intelligence Brief

human VWF/FVIII concentrate (human VWF/FVIII concentrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor replacement therapy. Area: Hematology.

phase 3 Coagulation factor replacement therapy Factor VIII Hematology Biologic Live · refreshed every 30 min

Target snapshot

human VWF/FVIII concentrate (human VWF/FVIII concentrate) — Octapharma. Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
human VWF/FVIII concentrate TARGET	human VWF/FVIII concentrate	Octapharma	phase 3	Coagulation factor replacement therapy	Factor VIII
Traditional Cryoprecipitate	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII
Kogenate (BAY 14-2222)	Kogenate (BAY 14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Factor VIII (rAHF)	Recombinant Factor VIII (rAHF)	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation Factor VIII
rFVIIIFc	rFVIIIFc	Bioverativ Therapeutics Inc.	marketed	Recombinant clotting factor (Factor VIII replacement therapy)	Factor VIII / FcRn (neonatal Fc receptor)
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Intravenous infusions of Xyntha	Intravenous infusions of Xyntha	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor replacement therapy class)

Hoffmann-La Roche · 2 drugs in this class
Genzyme, a Sanofi Company · 1 drug in this class
Octapharma · 1 drug in this class
Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). human VWF/FVIII concentrate — Competitive Intelligence Brief. https://druglandscape.com/ci/human-vwf-fviii-concentrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab